Generic Name and Formulations:
Timolol (as maleate) 0.5%; oph soln; contains benzalkonium chloride.
Bausch & Lomb Inc.
Indications for ISTALOL:
Open-angle glaucoma. Ocular hypertension.
1 drop in affected eye(s) once daily in the AM.
Greater than 1st-degree AV block. Overt cardiac failure. Cardiogenic shock. Sinus bradycardia. Bronchial asthma. Severe COPD. History of bronchospasm. Not for use as a sole agent in angle-closure glaucoma.
History of cardiac failure. Discontinue at 1st sign of cardiac failure, and before surgery. Avoid abrupt cessation. Diabetes. May mask hypoglycemia, thyrotoxicosis. Myasthenia gravis. Cerebrovascular insufficiency. Contact lenses (remove; may reinsert 15 min after instillation). Pregnancy (Cat.C). Nursing mothers: not recommended.
Avoid other topical β-blockers. May potentiate systemic β-blockers, reserpine, hypoglycemics, and mydriatic effect of topical epinephrine. May be potentiated by quinidine. May cause conduction defects with digoxin, calcium channel blockers (avoid concomitant use in impaired cardiac function).
Local irritation (burning, stinging), blurred vision, cataract, conjunctival injection, infection, headache, hypertension, itching. Systemic β-blocker effects (eg, bronchospasm, bradycardia, cardiac failure, muscle weakness).
- 5ml of 0.5% eye droppers (Qty:1)
- appx. price $289.00
- Recall of Two IV Antibiotics Announced
- Five Things ID Experts Want You to Know Before You Prescribe an Antibiotic
- What's Changed in Immunization Recommendations From CDC Advisory Committee
- Peanut Allergy Patch Shows Promise in Latest Study
- IUD Approval Gives Women New Long-Acting Birth Control Option
- FDA Issues Warning on Four Tainted Weight Loss Supplements
- FDA Wants More Info Before Approving Exparel for Post-Op Nerve Block
- First-In-Class Enzyme Replacement Therapy for Hypophosphatasia Under Review
- FDA to Review Lifitegrast for Dry Eye Disease
- BI Requesting Accelerated Approval for Pradaxa Reversal Agent